Registry-listed formulations

volociximab · mesh:C516631

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

3 source entries across 1 studies. This list may not include all unresolved or historical entries.

Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
60%(3/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Phase 1/2
1
17%
Phase 2
4
67%
Phase 1
1
17%

Phase Distribution

1

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 1/2Combined phases
1(16.7%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(2)
Other(1)

Detailed Status

Completed3
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (16.7%)
Phase 1/21 (16.7%)
Phase 24 (66.7%)

Trials by Status

terminated233%
completed350%
unknown117%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

NCT00782093
unknownphase_2

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00278187
completedphase_2

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

NCT00401570
completedphase_1_2

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

NCT00635193
terminatedphase_2

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

NCT00516841
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00782093Phase 1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

Completed
NCT00278187Phase 2

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Unknown
NCT00401570Phase 2

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

Completed
NCT00635193Phase 1/2

Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)

Completed
NCT00516841Phase 2

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Terminated
NCT00369395Phase 2

A Study of Volociximab in Metastatic Melanoma

Terminated

All 6 trials loaded

Drug Details

Intervention Type
Varies by study
Molecule Type
Antibody
Total Trials
6

External References

ChEMBL
CHEMBL2108061

Names & Codes

Research Codes

M-200